Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 628Stomach Neoplasms 76Neoplasm Metastasis 59Neoplasms 39HER2-positive Breast Cancer 33Breast Neoplasms, Male 30Colorectal Neoplasms 28Brain Neoplasms 25Carcinoma, Non-Small-Cell Lung 21Inflammatory Breast Neoplasms 20Esophageal Neoplasms 20Pancreatic Neoplasms 13Triple Negative Breast Neoplasms 12Lung Neoplasms 11Endometrial Neoplasms 11Ovarian Neoplasms 10Colonic Neoplasms 10Urinary Bladder Neoplasms 9Rectal Neoplasms 9Prostatic Neoplasms 9Cardiotoxicity 8Adenocarcinoma 8Salivary Gland Neoplasms 7Gallbladder Neoplasms 7Breast Diseases 7Biliary Tract Neoplasms 7Adenocarcinoma Of Esophagus 7Uterine Cervical Neoplasms 6Squamous Cell Carcinoma of Head and Neck 6Sarcoma 6

Interventions

Fulvestrant 3palbociclib 2Letrozole 2Anastrozole 2venetoclax 1pyrotinib 1pertuzumab 1penpulimab 1dalpiciclib 1anlotinib 1Tretinoin 1Trastuzumab 1Ropivacaine 1Radiosurgery 1Propofol 1Patient Reported Outcome Measures 1Paclitaxel 1Ondansetron 1Morphine 1Induction Chemotherapy 1Etoricoxib 1Docetaxel 1Diagnostic Imaging 1Carboplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Neoplasm Female × Trastuzumab × Clear all
NCT05577442 2022-10-19

Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy for HR +/HER2 + Advanced Breast Cancer

Peking University Cancer Hospital & Institute

Phase 2 Unknown
52 enrolled
Breast

Breast Neoplasm Female

Data powered by HemOnc (CC BY 4.0) Colophon âš¡